Resources from the same session
LBA8 - Phase II trial of atezolizumab plus carboplatin and paclitaxel in patients with metastatic or recurrent thymic carcinoma: Marble study
Presenter: Tomoyasu Mimori
Session: Proffered Paper session: Thoracic malignancies
Resources:
Abstract
Slides
Webcast
625O - Efficacy and safety of lucitanib (AL3810) in second or subsequent-line treatment of advanced recurrent or metastatic thymic carcinoma: A randomized, double-blind, placebo-controlled multicenter phase II trial
Presenter: Wentao Fang
Session: Proffered Paper session: Thoracic malignancies
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA8 and 625O
Presenter: Jordi Remon Masip
Session: Proffered Paper session: Thoracic malignancies
Resources:
Slides
Webcast
Q&A and discussion
Session: Proffered Paper session: Thoracic malignancies
Resources:
Webcast
LBA5 - Zongertinib in patients with HER2-mutant NSCLC: Updated analysis of beamion LUNG-1
Presenter: Noboru Yamamoto
Session: Proffered Paper session: Thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA6 - PACIFIC-5: A phase III study of consolidation durvalumab (D) in patients (pts) with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy (cCRT or sCRT)
Presenter: Yi-Long Wu
Session: Proffered Paper session: Thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA7 - Efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): A pooled analysis of TROPION-Lung01 and TROPION-Lung05
Presenter: Myung-Ju Ahn
Session: Proffered Paper session: Thoracic malignancies
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Session: Proffered Paper session: Thoracic malignancies
Resources:
Webcast